Overview

A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)

Status:
Recruiting

Trial end date:
2022-05-23

Target enrollment:

Participant gender:

Summary

The main objective of the study is to evaluate dose-exposure and safety of nintedanib in children and adolescents with fibrosing Interstitial Lung Disease (ILD).

Phase:

Phase 3

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Nintedanib